Table 1 Main characteristics of included studies
From: Prognostic value of microvessel density in cervical cancer
Study (year, population) | Age | FIGO stage | Sample size | Antibody | Follow-up (month) | Method for MVD | Cutoff of MVD | HR (95% CIs) | Survival analysis | Results | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|
Cantu et al. (2003, Mexico) [9] | 48 (28–70) | II–III | 118 | CD34 | 60 (median) | Hot spot | 20 | DFS: 1.63 (1.71–2.65) | DFS | Positive | 7 |
Cooper et al. (1998, England) [10] | 50 (29–81) | I–III | 111 | Anti-factor VIII | 55 (28–117) (median) | Hot spot | 10 | OS: 1.68 (1.03–2.74); DFS: 2.2 (1.09–4.44) | OS, DFS | Positive | 8 |
Dellas et al. (1997, Switzerland) [17] | NR | IB | 58 | CD31 | 67 (median) | Hot spot | NR | OS: 1.5 (1.04–2.16) | OS | Positive | 7 |
Hockel et al. (2001, Germany) [18] | NR | IB1–VIB | 52 | Anti-factor VIII | 26 (4–96) (median) | Hot spot | 40 | OS: 3.17 (1.32–7.63); DFS: 2.08 (1.22–3.54) | OS, DFS | Positive | 8 |
Kaku et al. (1998, Japan) [19] | 46 (25–67) | I–II | 56 | Anti-factor VIII | 99 (61–175) (median) | Hot spot | 75 | OS: 3.31 (1.21–9.07) | OS | Positive | 8 |
Lee et al. (2006, Korea) [11] | 48 (31–69) | IB–IIB | 85 | CD34 | 60 | IHC | 30.5 | OS: 1.11 (0.63–1.98); DFS: 1.04 (0.59–1.85) | OS, DFS | No significance | 9 |
Moriyama et al. (2009, Japan) [20] | 55.9 (33–72) | IB–IIB | 57 | Anti-factor VIII | 10.5–174.3 | Hot spot | 0.8% | OS: 2.92 (1.11–7.69) | OS | Positive | 8 |
Randall et al. (2009, America) [21] | 39.1 | IA2, IB, IIA | 173 | CD31, CD105 | 105.9 (2.7–184.8) (median) | Hot spot | 110 in CD31, 28 in CD105 | CD31-OS: 0.36 (0.17–0.79); CD105-OS: 1.76 (0.89–3.48) | OS | Positive in CD31 | 8 |
Schlenger et al. (1995, Germany) [22] | 53 (26–80) | IB–IVA | 39 | Anti-factor VIII | 18 (4–41) (median) | IHC | 83 | DFS: 1.46 (1.05–2.03) | DFS | Positive | 8 |
Tjalma et al. (1998, Belgium) [25] | 54 (24–91) | IA–IVB | 114 | CD31 | 39 (1–203) | Hot spot | 261 | OS: 2.17 (1.15–4.1) | OS | Positive | 7 |
Van et al. (2006, America) [24] | 42 ± 11 (26–79) | IB–IVA | 38 | CD31 | 17 ± 17 (1–71) (mean) | IHC | NR | OS: 2.54 (1.11–5.82) | OS | Positive | 7 |
Zijlmans et al. (2009, Netherlands) [23] | 45 (29–72) | IB–VIB | 30 | CD105 | NR | Hot Spot | NR | OS: 3.81 (0.46–31.42); DFS: 3.23 (1.38–7.57) | OS, DFS | Positive | 8 |
Obermair et al. (1998, Austria) [26] | 43 (23–70) | IB | 166 | Anti-factor VIII | 85 (5–170) (median) | Hot Spot | 20 | OS: 2.56 (1.59–4.11) | OS | Positive | 7 |